News
For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com
IceCure Announces 8-for-1 Reverse Stock Split in Preparation for Nasdaq Listing
CAESAREA, Israel, August 9, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS JULY 27 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Tuesday, July 27, 2021
IceCure Medical Announces Exclusive $6.6M Distribution Agreement to Sell ProSense™ Cryoablation System in Brazil
CAESAREA, Israel, June 7, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that
Positive Interim Results from IceCure Medical’s ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting
CAESAREA, Israel, May 3, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the minimally invasive cryoablation ProSense® System that destroys
IceCure Medical Announces Upcoming Presentation at the American Society of Breast Surgeons Annual Meeting
CAESAREA, Israel, April 20, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that
IceCure Medical Granted FDA Breakthrough Device Designation for ProSense® Cryoablation System
Treatment for patients with T1 invasive breast cancer and/or breast cancer for patients not suitable for surgical alternatives included in the indications being reviewed CAESAREA,
IceCure Announces 8-for-1 Reverse Stock Split in Preparation for Nasdaq Listing
CAESAREA, Israel, August 9, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS JULY 27 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Tuesday, July 27, 2021
IceCure Medical Announces Exclusive $6.6M Distribution Agreement to Sell ProSense™ Cryoablation System in Brazil
CAESAREA, Israel, June 7, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that
Positive Interim Results from IceCure Medical’s ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting
CAESAREA, Israel, May 3, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the minimally invasive cryoablation ProSense® System that destroys
IceCure Medical Announces Upcoming Presentation at the American Society of Breast Surgeons Annual Meeting
CAESAREA, Israel, April 20, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that
IceCure Medical Granted FDA Breakthrough Device Designation for ProSense® Cryoablation System
Treatment for patients with T1 invasive breast cancer and/or breast cancer for patients not suitable for surgical alternatives included in the indications being reviewed CAESAREA,